[go: up one dir, main page]

CY1119389T1 - METHOD FOR THE TREATMENT OF TREATMENT OF MULTIPLE SCIENCE - Google Patents

METHOD FOR THE TREATMENT OF TREATMENT OF MULTIPLE SCIENCE

Info

Publication number
CY1119389T1
CY1119389T1 CY20171100999T CY171100999T CY1119389T1 CY 1119389 T1 CY1119389 T1 CY 1119389T1 CY 20171100999 T CY20171100999 T CY 20171100999T CY 171100999 T CY171100999 T CY 171100999T CY 1119389 T1 CY1119389 T1 CY 1119389T1
Authority
CY
Cyprus
Prior art keywords
treatment
subject
treating
multiple sclerosis
multiple science
Prior art date
Application number
CY20171100999T
Other languages
Greek (el)
Inventor
Roland Martin
Henry F Mcfarland
Bibiana Bielekova
Original Assignee
The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119389(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services filed Critical The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services
Publication of CY1119389T1 publication Critical patent/CY1119389T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Εδώ αποκαλύπτεται μια μέθοδος για τη θεραπεία ενός υποκειμένου με πολλαπλή σκλήρυνση. Σε μια ενσωμάτωση, παρέχεται μια μέθοδος για τη θεραπεία ενός υποκειμένου με πολλαπλή σκλήρυνση που περιλαμβάνει τη χορήγηση στο υποκείμενο μιας θεραπευτικώς αποτελεσματικής ποσότητας από έναν ανταγωνιστή του υποδοχέα της IL-21, όπου το υποκείμενο έχει αποτύχει να αποκριθεί σε θεραπευτική αγωγή με βήτα ιντερφερόνη, θεραπεύοντας έτσι το υποκείμενο.A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis comprising administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond to treatment with beta interferon therapy. so the subject.

CY20171100999T 2002-06-28 2017-09-21 METHOD FOR THE TREATMENT OF TREATMENT OF MULTIPLE SCIENCE CY1119389T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39302102P 2002-06-28 2002-06-28
PCT/US2002/038290 WO2004002500A1 (en) 2002-06-28 2002-11-27 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
EP03762181.0A EP1539200B1 (en) 2002-06-28 2003-06-27 Method for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
CY1119389T1 true CY1119389T1 (en) 2018-02-14

Family

ID=30000962

Family Applications (2)

Application Number Title Priority Date Filing Date
CY2016043C CY2016043I2 (en) 2002-06-28 2016-12-09 METHOD FOR THE THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
CY20171100999T CY1119389T1 (en) 2002-06-28 2017-09-21 METHOD FOR THE TREATMENT OF TREATMENT OF MULTIPLE SCIENCE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY2016043C CY2016043I2 (en) 2002-06-28 2016-12-09 METHOD FOR THE THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS

Country Status (15)

Country Link
US (11) US7575742B2 (en)
EP (3) EP1539200B1 (en)
JP (8) JP2005535636A (en)
AU (3) AU2002368055B2 (en)
CA (3) CA2490804C (en)
CY (2) CY2016043I2 (en)
DK (2) DK1539200T3 (en)
ES (2) ES2474718T3 (en)
HK (2) HK1074769A1 (en)
HU (2) HUE036677T2 (en)
IL (2) IL165973A (en)
LU (1) LU93315I2 (en)
PT (2) PT1539200E (en)
SI (2) SI2314627T1 (en)
WO (2) WO2004002500A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2289045C2 (en) * 2001-04-26 2006-12-10 МОУШН ТЕКНОЛОДЖИЗ, ЛЛСи Infinitely variable gear box
CA2490804C (en) 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
PL1845925T3 (en) 2005-01-12 2017-05-31 Biogen Ma Inc. Method for delivering interferon-beta
WO2006089066A1 (en) * 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Combinations therapy for treatment of demyelinating conditions
JP2010525821A (en) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド Modified IFN beta polypeptides and their use
US20100055098A1 (en) * 2008-08-28 2010-03-04 Facet Biotech Corporation Method for treating multiple sclerosis patients with anti-il2r antibodies
JP2012505257A (en) * 2008-10-13 2012-03-01 バイオヴィスタ，インコーポレイテッド Compositions and methods for the treatment of multiple sclerosis
WO2010068923A2 (en) * 2008-12-12 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents that selectively inhibit cd25 on dendritic cells or t cells and their use
AU2010286427A1 (en) * 2009-08-31 2012-03-08 Abbott Biotherapeutics Corp. Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
JP6060073B2 (en) 2010-04-08 2017-01-11 ジェイエヌ バイオサイエンシーズ エルエルシー Antibody against CD122
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
US9809652B2 (en) 2011-08-08 2017-11-07 Abbvie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis comprising subcutaneously administering daclizumab
AU2016334085B2 (en) 2015-10-09 2019-11-21 Bioniz Therapeutics, Inc. Modulating gamma - c -cytokine activity
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
DE102017104088A1 (en) * 2017-02-28 2018-08-30 L&O Hunting Group GmbH Integral muffler for a rifle barrel
CN113874075A (en) 2019-05-03 2021-12-31 比奥尼斯有限责任公司 Effect of modulation of gamma C-cytokine signaling on the treatment of alopecia and alopecia-related disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4819150A (en) 1985-04-05 1989-04-04 Unisys Corporation Array for simulating computer functions for large computer systems
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5336489A (en) 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE3815472A1 (en) * 1988-05-06 1989-11-16 Centre Regional De Transfusion MONOCLONAL ANTICOERPER AND ITS USE
US5152980A (en) 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS.
US5620686A (en) 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
US5840496A (en) * 1990-10-09 1998-11-24 Chiron Corporation Method for diagnosing endometrial cancer
FR2672291A1 (en) 1991-01-31 1992-08-07 Inst Nat Sante Rech Med COMPOSITION OF ANTIBODIES DIRECTED AGAINST HUMAN OR ANIMAL INTERLEUKIN-2 RECEPTOR.
GB9115010D0 (en) 1991-07-11 1991-08-28 Wellcome Found Antibody
JPH05244982A (en) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5571507A (en) 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
US5843454A (en) 1993-05-07 1998-12-01 Akzo Nobel N.V. HIV immunogenic complexes
DE69424871T2 (en) 1993-08-27 2000-10-05 The Pillsbury Co., Minneapolis MECHANICAL GAS PURIFIER
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
WO1999007861A1 (en) * 1997-08-06 1999-02-18 Laboratório Medinfar-Produtos Farmacêuticos, Lda. DNA INTEGRATION INTO 'MYCOBACTERIUM spp.' GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM
WO2000025816A1 (en) 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
WO2001080891A1 (en) * 2000-04-25 2001-11-01 Nippon Organon K. K. Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same
ES2314067T3 (en) * 2001-04-06 2009-03-16 University Of Bristol USE OF CD 25 LINK MOLECULES IN STEROID RESISTANT PATIENTS.
CA2490804C (en) 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
WO2004003156A2 (en) 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production

Also Published As

Publication number Publication date
IL165973A0 (en) 2006-01-15
HK1249850A1 (en) 2018-11-16
ES2637011T3 (en) 2017-10-10
US20090175823A1 (en) 2009-07-09
AU2003247813A1 (en) 2004-01-19
DK1539200T3 (en) 2014-06-30
CA2490804A1 (en) 2004-01-08
CA2490186C (en) 2014-04-15
EP2314627B1 (en) 2017-07-26
JP2006508039A (en) 2006-03-09
US7575742B2 (en) 2009-08-18
ES2474718T3 (en) 2014-07-09
US20040109859A1 (en) 2004-06-10
US20130017152A1 (en) 2013-01-17
EP2314627A2 (en) 2011-04-27
PT2314627T (en) 2017-08-29
EP3269377A1 (en) 2018-01-17
JP2005535636A (en) 2005-11-24
CA2844639A1 (en) 2004-01-08
JP2016145220A (en) 2016-08-12
LU93315I2 (en) 2017-01-26
US7258859B2 (en) 2007-08-21
JP2013032372A (en) 2013-02-14
US20150337044A1 (en) 2015-11-26
CA2490804C (en) 2016-12-06
US20150010477A1 (en) 2015-01-08
AU2003247813B2 (en) 2008-06-05
US20050249704A1 (en) 2005-11-10
CY2016043I1 (en) 2017-04-05
PT1539200E (en) 2014-08-25
AU2002368055A1 (en) 2004-01-19
EP1539200B1 (en) 2014-05-28
EP1539200A4 (en) 2007-11-07
US20180237532A1 (en) 2018-08-23
US8298525B2 (en) 2012-10-30
JP2011157378A (en) 2011-08-18
US20170190779A1 (en) 2017-07-06
HUS1600050I1 (en) 2017-06-28
HK1074769A1 (en) 2005-11-25
AU2002368055B2 (en) 2008-09-18
US20130095069A1 (en) 2013-04-18
IL241920A0 (en) 2015-11-30
EP1539200A2 (en) 2005-06-15
WO2004002421A3 (en) 2004-09-02
WO2004002421A2 (en) 2004-01-08
EP2314627A3 (en) 2011-05-11
JP5905534B2 (en) 2016-04-20
AU2008212004B2 (en) 2010-10-21
US8636997B2 (en) 2014-01-28
CA2490186A1 (en) 2004-01-08
US20080038275A1 (en) 2008-02-14
US8454965B2 (en) 2013-06-04
SI2314627T1 (en) 2017-10-30
HUE036677T2 (en) 2018-07-30
AU2008212004A1 (en) 2008-09-25
JP2010132660A (en) 2010-06-17
DK2314627T3 (en) 2017-10-23
JP2013139478A (en) 2013-07-18
US20190002575A1 (en) 2019-01-03
AU2003247813C1 (en) 2010-07-22
CY2016043I2 (en) 2017-04-05
JP2014221813A (en) 2014-11-27
IL165973A (en) 2015-10-29
WO2004002500A1 (en) 2004-01-08
SI1539200T1 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
CY1119389T1 (en) METHOD FOR THE TREATMENT OF TREATMENT OF MULTIPLE SCIENCE
CY1107314T1 (en) METHOD OF THERAPEUTIC EDUCATION OF PATIENTS AFFECTED WITH CLASSIFICATION USING COMPOSITE INTEGRITY
CY1110013T1 (en) Combinations For Multiple Myeloma Therapy
CY1106283T1 (en) QUINOLINYL-PYRROLOPYRAZOLES
CY1116992T1 (en) METHOD OF TREATMENT OF STRENGTHENING ILL-17 ACTIVITY
CY1111478T1 (en) Indication of Progesterone Dosage in the Treatment of Traumatic Brain Injury
CY1108436T1 (en) ADMINISTRATION OF KASAKINOIDS
DK1151009T3 (en) Antimicrobial / endotoxin neutralizing polypeptide
ATE475414T1 (en) TUBERCULOSIS TREATMENT WITH PLEUROMUTILIN DERIVATIVES
NO20032027L (en) Effective anti-tumor treatments
EE200200107A (en) Use of a fast-acting selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of sexual dysfunction
DE60108489D1 (en) COMBINATION THERAPIES WITH VULNERABLE ACTIVITY
CY1105787T1 (en) THERAPEUTIC TREATMENT THE PREVENTION OF Atrophy OF THE URINOGENITARY SYSTEM AND ITS SYMPTOMS IN WOMEN
CY1106402T1 (en) METHOD OF TREATMENT OF TOURETTE SYNDROME
CY1108599T1 (en) APLIDIN IN TREATMENT OF MULTIPLE MYELOMA
CY1110538T1 (en) S-MIRTAZAPIN FOR EXTRA TREATMENT
MXPA06001828A (en) Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor.
CY1109001T1 (en) Kappa-like Fighters in the Treatment of Cystic Diseases
DK1030667T3 (en) Use of mirtazapine in the manufacture of a medicament for the treatment of sleep apnea
EA199800866A1 (en) METHOD OF REMOVAL OF PAIN
CY1115481T1 (en) METHOD FOR THE TREATMENT OF TREATMENT OF MULTIPLE SCIENCE
CY1106385T1 (en) USE OF EPOTHILONE DERIVATIVES IN THE TREATMENT OF SUBPARATHYROIDISM
ATE268170T1 (en) USE OF SUMMERIC ACID OR SALTS THEREOF TO TREAT INSULIN RESISTANCE
DE60313444D1 (en) VEGF-PEPTIDES AND ITS USE
NO20051936L (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes.